Mazdutide vs Semaglutide
Comparing Innovent's dual GLP-1/glucagon agonist mazdutide with established GLP-1 agonist semaglutide.
Last updated: February 1, 2026
Mazdutide
Semaglutide
Overview
Mazdutide (IBI362/LY3305677) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics in partnership with Eli Lilly. Like other dual agonists, it aims to leverage glucagon’s metabolic effects alongside GLP-1 for enhanced weight loss and metabolic benefits compared to GLP-1-only approaches.
Mechanism Comparison
| Aspect | Mazdutide | Semaglutide |
|---|---|---|
| Target Receptors | GLP-1 + Glucagon | GLP-1 only |
| Receptor Activity | Dual agonist | Single agonist |
| Developer | Innovent/Lilly | Novo Nordisk |
| Design Approach | Oxyntomodulin analog | GLP-1 analog |
Dual Agonist Rationale
Mazdutide combines:
- GLP-1 effects: appetite suppression, glucose control
- Glucagon effects: increased energy expenditure, hepatic lipid metabolism
- Oxyntomodulin-like structure provides balanced dual activity
Evidence Comparison
| Aspect | Mazdutide | Semaglutide |
|---|---|---|
| Development Stage | Phase 3 (China), Phase 2 (Global) | FDA Approved |
| Human Trials | Multiple (primarily China) | Extensive global |
| Regulatory Approval | China approval expected | US, EU, global |
| Long-term Safety | Limited | Extensive |
Clinical Trial Data
GLORY-1 (Chinese Population)
| Metric | Mazdutide 6mg | Mazdutide 9mg |
|---|---|---|
| Weight Loss (24wk) | ~11% | ~14% |
| Treatment Completion | High | High |
| GI Tolerability | Acceptable | More GI events |
Comparison Context
| Metric | Mazdutide 9mg | Semaglutide 2.4mg (STEP 1) |
|---|---|---|
| Approximate Weight Loss | ~14-17% | ~15% |
| Duration | 24-48 weeks | 68 weeks |
| Population | Primarily Chinese | Global |
Caveat: Cross-trial comparisons are limited; populations and protocols differ.
Regulatory Status
| Aspect | Mazdutide | Semaglutide |
|---|---|---|
| China Status | NDA submitted (2024) | Approved |
| US Status | Phase 2 | Approved |
| EU Status | Not yet filed | Approved |
| MASH Development | Not primary focus | Not indicated |
Administration
| Aspect | Mazdutide | Semaglutide |
|---|---|---|
| Route | Subcutaneous injection | SC injection + Oral |
Side Effect Profile
| Effect | Mazdutide | Semaglutide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| Diarrhea | Common | Common |
| Discontinuation Rate | Similar to class | ~7% (STEP trials) |
Both medications have typical incretin-class GI side effects.
Market Context
| Factor | Mazdutide | Semaglutide |
|---|---|---|
| Primary Market | China initially | Global |
| Supply Chain | Innovent manufacturing | Novo Nordisk |
| Pricing Strategy | Expected lower (China) | Premium pricing |
| Access Issues | None (in China) | Global shortages |
Key Differences
- Geographic focus: Mazdutide primarily developed for Chinese market initially
- Dual mechanism: Glucagon component may provide metabolic advantages
- Approval status: Semaglutide is globally approved; mazdutide is investigational
- Data maturity: Semaglutide has years of real-world evidence
- CV outcomes: Semaglutide has SELECT trial; mazdutide CV outcomes unknown
Summary
- Mazdutide is a promising dual GLP-1/glucagon agonist with strong Chinese clinical data
- Semaglutide remains the established standard with global approval and CV benefit data
- Dual agonism theoretically offers metabolic advantages but requires more validation
- Market dynamics may differ significantly between China and Western markets
This comparison is for educational purposes only. Mazdutide is investigational outside of approved markets. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.